Physician profile
Benjamin H Ticho
NPI 1992782494
$8,334.91
in general payments reported to CMS, 2019-2025
33 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $541 · 2021: $957 · 2022: $1,650 · 2023: $1,157 · 2024: $2,383 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395 · Consulting Fee: $1,200 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.14 |
| Consulting Fee | $1,200.00 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,560.74 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $764.20 | 2021-2023 | Acthar |
| Sight Sciences, INC. | $715.53 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Alcon Vision LLC | $701.91 | 2019-2025 | Clareon, Acrysof Iq Vivity, Hydrus Microstent |
| Abbvie INC. | $659.09 | 2022-2025 | Durysta, Botox, Xen Glaucoma Treatment System |
| Horizon Therapeutics Plc | $608.81 | 2020-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $461.89 | 2019-2025 | Xelpros, Cequa |
| New World Medical,INC. | $423.19 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Allergan, INC. | $355.80 | 2020-2022 | |
| Merz North America, INC. | $327.65 | 2022 | |
| Bausch & Lomb Americas INC. | $255.91 | 2023-2025 | Infuse Multifocal, Miebo, Xiidra |
| Biotissue Holdings INC. | $172.24 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $169.63 | 2020-2023 | |
| Abb Con-Cise Optical Group LLC | $154.84 | 2019-2024 | Contact Lens, Spectacle Lenses |
| Eyevance Pharmaceuticals LLC | $148.27 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $138.20 | 2021-2024 | Veritas Vision System |
| Tarsus Pharmaceuticals, INC. | $116.84 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $99.22 | 2019-2023 | Istent Inject Trabecular Micro-Bypass System, Istent Inject Trabecular Micro-Bypass System |
| Dompe US, INC. | $89.24 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $74.10 | 2024 | Vevye |
| Iridex Corporation | $52.27 | 2023 | |
| Beaver-Visitec International, INC. | $48.16 | 2024 | |
| Lkc Technologies, INC. | $36.78 | 2025 | |
| Travere Therapeutics, INC. | $31.48 | 2022-2023 | Cholbam |
| Astellas Pharma US INC | $29.41 | 2025 | Izervay |
| Rayner Intraocular Lenses Limited | $27.19 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Rxsight INC | $23.27 | 2021 | |
| Merz Pharmaceuticals, LLC | $20.56 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oasis Medical, INC. | $18.64 | 2020 | |
| Ocular Therapeutix, INC. | $15.34 | 2022 | |
| Boston Scientific Corporation | $15.11 | 2023 | Advantage System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Ticho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.